| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
1,250,000,000 |
| Market
Cap: |
88.41(B) |
| Last
Volume: |
10,911,418 |
Avg
Vol: |
8,708,716 |
| 52
Week Range: |
$63.15 - $87.29 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
NASDAQ-100 |
| |
S&P 500 |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 259 |
| Guru Rank Value : 4.6 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Co.'s primary areas of focus include viral diseases, inflammatory diseases and oncology. Co.'s products include: Biktarvy® for the treatment of HIV-1 infection in certain patients; Veklury® (remdesivir), for the treatment of Coronavirus Disease 2019 requiring hospitalization; Epclusa® for the treatment of chronic hepatitis C virus infection; Vemlidy® for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease; Yescarta® (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
2,000 |
25,472 |
36,973 |
80,792 |
| Total Sell Value |
$145,920 |
$2,022,270 |
$2,937,849 |
$6,445,296 |
| Total People Sold |
1 |
3 |
3 |
4 |
| Total Sell Transactions |
1 |
5 |
8 |
14 |
| End Date |
2024-03-24 |
2023-12-22 |
2023-06-23 |
2022-06-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Meyers James R |
EVP Worldwide Commercial Ops |
• • – |
2017-08-10 |
4 |
GA |
$0.00 |
$0 |
I/I |
525 |
126,030 |
|
- |
|
| Meyers James R |
EVP Worldwide Commercial Ops |
• • – |
2017-08-10 |
4 |
GD |
$0.00 |
$0 |
D/D |
525 |
2,715 |
|
- |
|
| Meyers James R |
EVP Worldwide Commercial Ops |
• • – |
2017-08-10 |
4 |
D |
$72.70 |
$21,447 |
D/D |
(295) |
3,240 |
|
- |
|
| Meyers James R |
EVP Worldwide Commercial Ops |
• • – |
2017-08-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
820 |
3,535 |
|
- |
|
| Martin John C |
Executive Chairman |
• • – |
2017-08-01 |
4 |
AS |
$75.86 |
$5,562,777 |
D/D |
(73,333) |
3,126,636 |
|
- |
|
| Martin John C |
Executive Chairman |
• • – |
2017-08-01 |
4 |
OE |
$21.58 |
$1,582,159 |
D/D |
73,333 |
3,199,969 |
|
- |
|
| Alton Gregg H |
EVP Comm&Acs ALA, Corp&Med Aff |
• • – |
2017-08-01 |
4 |
AS |
$75.88 |
$1,138,190 |
D/D |
(15,000) |
91,113 |
|
- |
|
| Alton Gregg H |
EVP Comm&Acs ALA, Corp&Med Aff |
• • – |
2017-08-01 |
4 |
OE |
$26.99 |
$232,789 |
D/D |
8,625 |
106,113 |
|
- |
|
| Alton Gregg H |
EVP Comm&Acs ALA, Corp&Med Aff |
• • – |
2017-07-21 |
4 |
AS |
$74.00 |
$2,960,000 |
D/D |
(40,000) |
97,488 |
|
- |
|
| Alton Gregg H |
EVP Comm&Acs ALA, Corp&Med Aff |
• • – |
2017-07-21 |
4 |
OE |
$26.99 |
$931,155 |
D/D |
34,500 |
137,488 |
|
- |
|
| Martin John C |
Executive Chairman |
• • – |
2017-07-03 |
4 |
AS |
$71.00 |
$5,206,892 |
D/D |
(73,333) |
3,126,636 |
|
- |
|
| Martin John C |
Executive Chairman |
• • – |
2017-07-03 |
4 |
OE |
$21.58 |
$1,582,159 |
D/D |
73,333 |
3,199,969 |
|
- |
|
| Alton Gregg H |
EVP Comm&Acs ALA, Corp&Med Aff |
• • – |
2017-07-03 |
4 |
AS |
$71.06 |
$355,295 |
D/D |
(5,000) |
102,988 |
|
- |
|
| Martin John C |
Executive Chairman |
• • – |
2017-06-01 |
4 |
AS |
$65.24 |
$4,784,531 |
D/D |
(73,333) |
3,199,969 |
|
- |
|
| Martin John C |
Executive Chairman |
• • – |
2017-06-01 |
4 |
OE |
$21.58 |
$1,582,159 |
D/D |
73,333 |
3,273,302 |
|
- |
|
| Alton Gregg H |
EVP Comm&Acs ALA, Corp&Med Aff |
• • – |
2017-06-01 |
4 |
AS |
$65.02 |
$325,114 |
D/D |
(5,000) |
107,988 |
|
- |
|
| Young Kevin |
Chief Operating Officer |
• • – |
2017-05-10 |
4 |
D |
$66.92 |
$231,543 |
D/D |
(3,460) |
6,231 |
|
- |
|
| Young Kevin |
Chief Operating Officer |
• • – |
2017-05-10 |
4 |
A |
$0.00 |
$0 |
D/D |
6,810 |
9,691 |
|
- |
|
| Wold Olsen Per |
Director |
• • – |
2017-05-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,787 |
93,330 |
|
- |
|
| Madigan John W |
Director |
• • – |
2017-05-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,787 |
18,548 |
|
- |
|
| Wilson Gayle E |
Director |
• • – |
2017-05-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,787 |
122,258 |
|
- |
|
| Lofton Kevin E |
Director |
• • – |
2017-05-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,787 |
30,124 |
|
- |
|
| Cogan John Francis |
Director |
• • – |
2017-05-09 |
4 |
AS |
$67.25 |
$668,667 |
D/D |
(9,943) |
52,619 |
|
- |
|
| Cogan John Francis |
Director |
• • – |
2017-05-09 |
4 |
OE |
$0.00 |
$310,575 |
D/D |
16,787 |
62,562 |
|
- |
|
| Alton Gregg H |
EVP Comm&Acs ALA, Corp&Med Aff |
• • – |
2017-05-01 |
4 |
AS |
$68.31 |
$341,529 |
D/D |
(5,000) |
112,988 |
|
- |
|
1105 Records found
|
|
Page 24 of 45 |
|
|
0.06 (0.08%) 
